Latest Dorsavi (ASX:DVL) News

Space batteries, telecom AI and a healthcare software leadership change drove the week’s biggest moves in small-cap tech. Capital raisings and debt deals also shaped trading, with several early jumps fading as investors weighed dilution and execution risk.

dorsaVi has completed the design of its first integrated RRAM-CMOS validation chip, featuring self-checking write-and-verify, compute-in-memory capabilities, and scalable integration on commercial CMOS wafers. The milestone sets the stage for fabrication and commercial engagement in high-value edge AI markets.

dorsaVi has raised $500,000 through the exercise of 25 million unlisted options by key shareholders, reinforcing confidence in its advanced AI and neuromorphic semiconductor projects. The capital will accelerate development of its 22nm node technology targeting medical and industrial robotics markets.

A brutal sell-off in a few small caps sat alongside takeover bids, fresh capital raisings and strong gains in medtech. The week split the market in two: buyers chased clear funding and approval news, while weaker stories sank fast after reopening.

Capital raisings drove the week in ASX tech, with investors backing AI and data centre spending but punishing deep discounts. The biggest moves came from small-cap fundraisings, while AI infrastructure names drew the clearest buying support.

dorsaVi has secured exclusive rights to two key robotics patents from NTU Singapore, filling critical gaps in safety control and data acquisition to expand into collaborative robotics and exoskeleton markets.

A handful of extreme moves set the tone, from DXN’s explosive AI data centre rerating to steep sell-offs in small-cap explorers. Deals, funding and fresh drilling results drove the week, but several gap-ups lost steam as traders banked profits.

AI infrastructure names drove the biggest moves this week, with DXN exploding higher and Stakk extending its run after a new US healthcare contract. Elsewhere, capital raisings, takeover moves and executive changes kept tech investors busy, while several early gap-ups faded as buying cooled.

dorsaVi reveals that integrating RRAM and neuromorphic computing into its sensor platform could halve sensor count and more than double battery life in lower-limb exoskeletons, positioning the company as a key intelligence partner in a $1.79 billion market.

Battery tech, biotech and balance-sheet repair drove the biggest gains this week, while guidance cuts and weak post-halt trading hurt several names. Deal-making and fresh equity funding stayed busy, especially in rare earths, defence and gold.

Capital moves, contract wins and AI product pushes drove a busy week across small and mid-cap technology stocks. Hydrix, Complii and ClearVue led the board, while investors sold names where early excitement gave way to dilution concerns or softer earnings detail.

dorsaVi has qualified three RRAM material stacks compatible with standard foundry processes, paving the way for scalable 22nm RRAM production and advancing its wearable robotics and medical sensor ambitions.